ORPHA:306542
Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome
Also known as: ALX1-related frontonasal dysplasia · Frontonasal dysplasia type 3
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
8
19.9th percentile
Trials
0
Interventional, condition-specific
Researchers
46
Distinct authors in sample
Gene link
ALX1
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Frontonasal -severe microphthalmia-severe facial clefting syndrome is a rare, genetic, orofacial clefting syndrome characterized by severe frontonasal with complete cleft palate, facial cleft, extreme microphtalmia and hypertelorism, frequently associated with eyelid colobomata, sparse or absent eyelashes/eyebrows, wide nasal bridge with hypoplastic alae nasi, low-set, posteriorly rotated ears and caudal appendage in the sacral region.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0013271
- OMIM:613456
- UMLS:C3150706
Additional Mondo synonyms (1)
frontonasal dysplasia type 3
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — ALX1
- LiteraturePresent
8 matched papers (5 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ALX1).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
8
8 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
8 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5 in the last 10 years · high confidence · 19.9th percentile (publications denominator)
Phrase hits: 8 · MeSH hits: 0
Who's working on it?
46
Distinct author names in 8 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Carmichael N2 papers · 2022
Department of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC - 02Cotney J2 papers · 2022
Genetics and Genome Sciences, UConn Health, Farmington, CT, USA.
Papers in Europe PMC - 03Grinblat Y2 papers · 2022
Departments of Integrative Biology, Neuroscience, and Genetics Ph.D. Training Program, University of Wisconsin-Madison, Madison, WI, USA.
Papers in Europe PMC - 04Hu YD2 papers · 2022
Center for Regenerative Medicine, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Papers in Europe PMC - 05Jiang R2 papers · 2024
Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Papers in Europe PMC - 06Kawasaki K2 papers · 2022
Center for Regenerative Medicine, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Papers in Europe PMC - 07Kueper J2 papers · 2022
Center for Regenerative Medicine, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Papers in Europe PMC - 08Lan Y2 papers · 2024
Division of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Papers in Europe PMC - 09Liao EC2 papers · 2022
Center for Regenerative Medicine, Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
Papers in Europe PMC - 10Maas RL2 papers · 2022
Department of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category frontonasal dysplasia also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: frontonasal dysplasia
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome" OR "ALX1-related frontonasal dysplasia" OR "Frontonasal dysplasia type 3"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Frontonasal dysplasia-severe microphthalmia-severe facial clefting syndrome" OR "ALX1-related frontonasal dysplasia" OR "Frontonasal dysplasia type 3" OR "ALX1"
Recall-expansion terms: ALX1
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"frontonasal dysplasia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:47:44.450Z